You’ve Gotta Have Heart: Positive Outlook Increases Heart Patients' Survival (DukeHealth.org)
Feb. 28, 2011
Cardiac patients with optimistic expectations about their recovery were 30 percent less likely to die over the next 15 years than patients with less optimistic expectations, regardless of the severity of their heart disease, according to researchers at Duke University Medical Center.
Implantable Heart Defibrillators Too Widely Used in High-Risk Patients (DukeHealth.org)
Jan. 5, 2011
More than one in five patients who receive implantable cardioverter-defibrillators (ICDs) do not meet evidence-based guidelines to receive them, significantly increasing their risk of complications and death, according to a new study published in the Journal of the American Medical Association and led by the Duke Clinical Research Institute.
Statewide Program Speeds Up Heart Attack Care in North Carolina (DukeHealth.org)
Nov. 16, 2010
A program designed to speed up heart attack care has led to significant improvement in the quality of care for heart attack patients after it was extended across North Carolina last year, according to researchers at Duke University Medical Center.
Major Study Shows Ability of New Agent to Prevent Strokes in Patients with Atrial Fibrillation (DukeHealth.org)
Nov. 15, 2010
In the primary result from the largest double-blind study ever completed to assess a drug’s effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting drug, was shown to be superior to warfarin, the current standard for treatment of atrial fibrillation, while patients in the study were taking study drug. However, the full intention-to-treat analysis, which includes patients who discontinued study drug, showed that rivaroxaban was non inferior to warfarin for the prevention of stroke or blood clots but did not demonstrate statistical superiority.
World’s Largest Heart Failure Study Finally Answers Questions About Nesiritide (DukeHealth.org)
Nov. 15, 2010
Results from the largest acute heart failure study ever conducted have resolved safety questions raised five years ago about the acute heart failure medication nesiritide (Natrecor), but more importantly illustrate the need for comprehensive, large, real world studies of investigational agents early in the course of development of new therapies, according to researchers at the Duke Clinical Research Institute.